Fulminant liver failure models with subsequent encephalopathy in the mouse

Area of Science:

• Hepatology
• Toxicology
• Animal Models

Background:

• Fulminant liver failure (FLF) lacks a consistently reliable animal model.
• Developing such a model is critical for advancing research in liver disease.

Purpose of the Study:

• To develop and validate a murine model for fulminant liver failure (FLF).
• To compare two distinct methods for inducing FLF in mice: azoxymethane (AOM) and galactosamine/tumor necrosis factor-alpha (Gal+TNF-alpha).
• To investigate the impact of body temperature (BT) control on the reliability of these FLF models.

Main Methods:

• Three groups of male C57BL/6 mice were used: control, AOM-treated, and Gal+TNF-alpha-treated.
• The study evaluated the effects of body temperature (BT) control on survival, histopathology, and biochemical/coagulation profiles.
• Neurological behavior was assessed using a coma scale, and dose-dependent survival curves were generated.

Main Results:

• Azoxymethane (AOM) treatment yielded a more consistent FLF model, particularly with body temperature (BT) control, compared to the Gal+TNF-alpha group.
• Histopathological findings confirmed FLF in both experimental groups when BT was controlled.
• Significant differences were observed in liver enzymes, prothrombin time-international normalized ratios (PT-INRs), and neurological coma stages between the models and hydration conditions.

Conclusions:

• The azoxymethane (AOM) model is effective for inducing fulminant liver failure (FLF) in mice but necessitates stringent body temperature (BT) management and a controlled environment.
• The choice of FLF model should align with specific research objectives.
• Meticulous animal care and close monitoring are essential for the successful development and utilization of FLF models.